Related Experiment Video
Updated: Aug 2, 2025
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Repeat stereotactic body radiotherapy for oligometastatic disease
Jonas Willmann1, Selma Adilovic2, Eugenia Vlaskou Badra2
1Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland; Center for Proton Therapy, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen, Switzerland.
Repeat stereotactic body radiotherapy (SBRT) for oligometastatic disease (OMD) shows shorter progression-free survival but longer overall survival. Further research is needed to identify patients who benefit most from repeat SBRT.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Oligometastatic disease (OMD) patients treated with metastasis-directed definitive local therapy, such as stereotactic body radiotherapy (SBRT), face the risk of new metastases.
- This study compares outcomes between patients receiving a single course versus repeat SBRT for OMD.
Purpose of the Study:
- To compare the characteristics and outcomes of OMD patients treated with single-course SBRT versus repeat SBRT.
- To identify patient and treatment factors predicting the use of repeat SBRT.
Main Methods:
- Retrospective analysis of 385 OMD patients treated with SBRT to 1-5 metastases.
- Comparison of progression-free survival (PFS), widespread failure-free survival (WFFS), overall survival (OS), and systemic therapy-free survival (STFS).
- Univariable and multivariable logistic regression to identify predictors of repeat SBRT.
Main Results:
- Repeat SBRT was used in 129 patients, single-course SBRT in 256. Lung cancer and metachronous oligorecurrence were most common.
- Repeat SBRT patients had significantly shorter PFS (p < 0.0001) but longer median OS (p = 0.01).
- WFFS and STFS were comparable between groups. Distant failure was more common in repeat SBRT patients. Low distant metastases velocity and prior systemic therapy lines predicted repeat SBRT use.
Conclusions:
- Despite shorter PFS, repeat SBRT in OMD patients is associated with longer OS.
- Further prospective studies are warranted to identify predictive factors for selecting patients who may benefit from repeat SBRT.
